Do analysts rate POAI or NDRA?

ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend NDRA or RVP?

ENDRA Life Sciences presently has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to NDRA or RVP?

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Retractable Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IRIX or NDRA more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets IRIDEX -6.23% N/A -11.16% ENDRA Life Sciences N/A -433.64% -204.58%

Does the media favor IRIX or NDRA?

In the previous week, IRIDEX and IRIDEX both had 1 articles in the media. IRIDEX's average media sentiment score of 0.75 beat ENDRA Life Sciences' score of 0.00 indicating that IRIDEX is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ENDRA Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ENDRA Life Sciences (NDRA) Competitors

$4.72 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.54 -0.18 (-3.73%)

As of 07/2/2026 04:54 PM Eastern

Compare

NDRA vs. CTSO, POAI, RVP, IRIX, and LFWD

Should you buy ENDRA Life Sciences stock or one of its competitors? MarketBeat compares ENDRA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ENDRA Life Sciences include Cytosorbents (CTSO), Predictive Oncology (POAI), Retractable Technologies (RVP), IRIDEX (IRIX), and Lifeward (LFWD). These companies are all part of the "medical equipment" industry.

How does ENDRA Life Sciences compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

ENDRA Life Sciences has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.66	-$8.20M	-$0.19	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ENDRA Life Sciences has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Cytosorbents. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company	Overall Sentiment
Cytosorbents	Neutral
ENDRA Life Sciences	Neutral

Cytosorbents has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,278.21%. ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 429.66%. Given Cytosorbents' higher probable upside, equities research analysts plainly believe Cytosorbents is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cytosorbents beats ENDRA Life Sciences on 7 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

ENDRA Life Sciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. ENDRA Life Sciences' return on equity of -433.64% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
ENDRA Life Sciences	Neutral

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

ENDRA Life Sciences has lower revenue, but higher earnings than Predictive Oncology. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Summary

ENDRA Life Sciences beats Predictive Oncology on 10 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Retractable Technologies?

ENDRA Life Sciences (NASDAQ:NDRA) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 59.5% of Retractable Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Retractable Technologies has higher revenue and earnings than ENDRA Life Sciences. Retractable Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A
Retractable Technologies	$37.15M	0.59	-$7.01M	-$0.21	N/A

ENDRA Life Sciences has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Retractable Technologies' return on equity of -17.15% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-433.64%	-204.58%
Retractable Technologies	-41.11%	-17.15%	-9.33%

In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 1 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Retractable Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ENDRA Life Sciences presently has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe ENDRA Life Sciences is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Retractable Technologies beats ENDRA Life Sciences on 8 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

ENDRA Life Sciences has a net margin of 0.00% compared to IRIDEX's net margin of -6.23%. IRIDEX's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	N/A	-11.16%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, IRIDEX and IRIDEX both had 1 articles in the media. IRIDEX's average media sentiment score of 0.75 beat ENDRA Life Sciences' score of 0.00 indicating that IRIDEX is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ENDRA Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IRIDEX presently has a consensus target price of $3.00, suggesting a potential upside of 165.49%. ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 429.66%. Given ENDRA Life Sciences' higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has higher revenue and earnings than ENDRA Life Sciences. IRIDEX is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.37	-$4.44M	-$0.19	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 8.6% of IRIDEX shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IRIDEX has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Summary

IRIDEX beats ENDRA Life Sciences on 8 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Lifeward?

Lifeward (NASDAQ:LFWD) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

ENDRA Life Sciences has lower revenue, but higher earnings than Lifeward. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$20.92M	1.08	-$19.91M	-$19.66	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Lifeward currently has a consensus price target of $10.00, indicating a potential upside of 24.69%. ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 429.66%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

26.8% of Lifeward shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.5% of Lifeward shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ENDRA Life Sciences has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Lifeward. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Lifeward. Lifeward's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company	Overall Sentiment
Lifeward	Neutral
ENDRA Life Sciences	Neutral

Lifeward has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Summary

ENDRA Life Sciences beats Lifeward on 7 of the 13 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NDRA vs. The Competition

Export

Metric	ENDRA Life Sciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.00M	$7.57B	$7.16B	$12.48B
Dividend Yield	N/A	1.32%	2.66%	6.52%
P/E Ratio	-0.58	52.12	28.02	24.70
Price / Sales	N/A	49.46	540.37	99.49
Price / Cash	N/A	26.72	49.26	57.09
Price / Book	2.46	7.48	10.96	6.46
Net Income	-$7.03M	$159.19M	$3.57B	$337.01M
7 Day Performance	-5.41%	-0.39%	2.12%	1.69%
1 Month Performance	11.58%	-0.43%	5.25%	3.81%
1 Year Performance	36.61%	3.14%	33.29%	23.90%

ENDRA Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NDRA ENDRA Life Sciences	2.1701 of 5 stars	$4.72 flat	$25.00 +429.7%	+36.6%	$6.00M	N/A	N/A	20	News Coverage
CTSO Cytosorbents	2.4852 of 5 stars	$0.43 +3.9%	$5.38 +1,152.9%	-62.5%	$25.93M	$37.06M	N/A	220
POAI Predictive Oncology	N/A	$7.14 +0.3%	N/A	-44.6%	$24.23M	$1.66M	N/A	30	Gap Down
RVP Retractable Technologies	N/A	$0.69 +1.5%	N/A	+12.2%	$20.56M	$37.15M	N/A	240
IRIX IRIDEX	2.6467 of 5 stars	$1.18 -0.4%	$3.00 +155.3%	+23.4%	$20.54M	$52.67M	N/A	120	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. CTSO, POAI, RVP, IRIX, and LFWD

How does ENDRA Life Sciences compare to Cytosorbents?

Summary

How does ENDRA Life Sciences compare to Predictive Oncology?

Summary

How does ENDRA Life Sciences compare to Retractable Technologies?

Summary

How does ENDRA Life Sciences compare to IRIDEX?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. CTSO, POAI, RVP, IRIX, and LFWD

How does ENDRA Life Sciences compare to Cytosorbents?

Which has better earnings and valuation, CTSO or NDRA?

Do institutionals & insiders believe in CTSO or NDRA?

Is CTSO or NDRA more profitable?

Does the media prefer CTSO or NDRA?

Which has more volatility and risk, CTSO or NDRA?

Do analysts recommend CTSO or NDRA?

Summary

How does ENDRA Life Sciences compare to Predictive Oncology?

Is POAI or NDRA more profitable?

Do analysts rate POAI or NDRA?

Does the media favor POAI or NDRA?

Do insiders & institutionals believe in POAI or NDRA?

Which has more risk and volatility, POAI or NDRA?

Which has preferable earnings and valuation, POAI or NDRA?

Summary

How does ENDRA Life Sciences compare to Retractable Technologies?

Do insiders and institutionals believe in NDRA or RVP?

Which has more volatility & risk, NDRA or RVP?

Which has better valuation & earnings, NDRA or RVP?

Is NDRA or RVP more profitable?

Does the media refer more to NDRA or RVP?

Do analysts recommend NDRA or RVP?

Summary

How does ENDRA Life Sciences compare to IRIDEX?

Is IRIX or NDRA more profitable?

Does the media favor IRIX or NDRA?

Do analysts recommend IRIX or NDRA?

Which has stronger valuation and earnings, IRIX or NDRA?

Do institutionals & insiders have more ownership in IRIX or NDRA?

Which has more risk and volatility, IRIX or NDRA?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Which has stronger valuation and earnings, LFWD or NDRA?

Do analysts rate LFWD or NDRA?

Do insiders & institutionals hold more shares of LFWD or NDRA?

Is LFWD or NDRA more profitable?

Does the media prefer LFWD or NDRA?

Which has more volatility & risk, LFWD or NDRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools